Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of AL001 in GRN or C9orf72 mutation carriers with frontotemporal dementia
2019-000138-20Phase 2Unknown
- Sponsor
- Alector
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AL001 in frontotemporal dementia (FTD), sponsored by Alector. Primary endpoint: Primary Safety Endpoints. Status: unknown.
02
Drugs
AL001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2019-000138-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000138-20.